News und Analysen
Vertex Pharmaceuticals: The Gilead Sciences of Cystic Fibrosis?
In only a year, Vertex Pharmaceuticals (NASDAQ: VRTX) has grown from a market cap of around $20 billion to knocking on the door of a $40 billion market cap. The biotech isn't finished growing.....
This Marijuana Stock May Already Be Running Out of Chances to Succeed
In case you haven't noticed, the marijuana industry is growing by leaps and bounds. According to cannabis research firm ArcView, the legal weed industry in North America is estimated to grow by....
5 Drugs That Could Make Celgene the Best Biotech Stock of the Next Decade
Over the past five years, Celgene (NASDAQ: CELG) stock has soared 280%. That's better than any other biotech with a market cap of $50 billion or more.Celgene's past success stemmed primarily from....
Johnson & Johnson Investors, Mark Your Calendars for October
After a nice jump in the first half of 2017, Johnson & Johnson (NYSE: JNJ) stock has largely tread water over the last few months. Wouldn't it be nice if the healthcare giant had a catalyst or....
Johnson & Johnson Investors, Mark Your Calendars for October
After a nice jump in the first half of 2017, Johnson & Johnson (NYSE: JNJ) stock has largely tread water over the last few months. Wouldn't it be nice if the healthcare giant had a catalyst or....
Axovant Sciences' Alzheimer's Disease Trial Comes Up Empty -- What Now?
Historically, 99% of Alzheimer's disease drugs to enter clinical trials have failed, yet Axovant Sciences (NASDAQ: AXON) believed it could design a phase 3 trial for its Alzheimer's disease drug,....
Axovant Sciences' Alzheimer's Disease Trial Comes Up Empty -- What Now?
Historically, 99% of Alzheimer's disease drugs to enter clinical trials have failed, yet Axovant Sciences (NASDAQ: AXON) believed it could design a phase 3 trial for its Alzheimer's disease drug,....
ALPHA MOS : INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE
INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS PREVUES PAR L'ARTICLE L. 233-8 II DU CODE DE COMMERCE ET L'ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AUTORITE DES MARCHES....
Here's Why PTC Therapeutics, Inc. Is Slipping Today
Shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) have fallen 17.3% as of 11:53 a.m. EDT on Tuesday. Recently released briefing documents left investors even less hopeful an upcoming independent....
3 Biotech Stocks With Major Catalysts in October
Every month brings plenty of catalysts for several biotech stocks. October is no exception. There are quite a few regulatory decisions and clinical results expected to be announced next....
3 Biotech Stocks With Major Catalysts in October
Every month brings plenty of catalysts for several biotech stocks. October is no exception. There are quite a few regulatory decisions and clinical results expected to be announced next....
3 Reasons to Buy the Dip With Exelixis
In just two days, Exelixis (NASDAQ: EXEL) has lost over 15% of its market cap. The tumble for the once-hot biotech stock started last week with a downgrade of the stock by an analyst at Leerink....
3 Bargain Biotech Stocks You Can Buy Today
You might have heard that the stock market is overpriced after years of solid gains. And it is. That doesn't mean every stock is overpriced, though.Actually, several biotech stocks look....
Why Celldex Therapeutics, Inc. Jumped Higher Today
Celldex Therapeutics (NASDAQ: CLDX) closed on Monday up 12.8%, with no apparent news to justify the double-digit gain by the biotech company.The move follows an 8.1% jump on Friday. Sometimes,....
3 Warren Buffett Stocks for Retirees
Warren Buffett is arguably the most revered investor on the planet. Over the course of more than six decades he's turned less than $10,000 into a net worth of nearly $79 billion. What's truly....
3 Warren Buffett Stocks for Retirees
Warren Buffett is arguably the most revered investor on the planet. Over the course of more than six decades he's turned less than $10,000 into a net worth of nearly $79 billion. What's truly....
This Marijuana Stock Is On an 8-Day Losing Streak -- Is It Time to Buy?
Over the trailing year, there's arguably been no better-performing industry than marijuana and marijuana stocks. A majority of pot stocks have moved significantly higher over the past year, with a....
3 Top Marijuana Stocks to Buy This Fall
Marijuana stocks weren't all that hot in the first half of 2017. The situation began to turn around for several leading marijuana stocks in the summer, though. What's the outlook for fall? Pretty....
AbbVie's Unfazed by the Risk of Generic Humira
Over 60% of AbbVie Inc.’s (NYSE: ABBV) sales come from demand for Humira -- an autoimmune-disease drug prescribed to patients with a variety of conditions -- that racks up sales of $16 billion per....
Better Buy: Kimberly-Clark Corp. vs. Johnson & Johnson
There aren't many companies that can grow sales and profits through a wide range of market conditions. But both Kimberly-Clark (NYSE: KMB), the consumer goods specialist, and Johnson & Johnson....
Better Buy: Kimberly-Clark Corp. vs. Johnson & Johnson
There aren't many companies that can grow sales and profits through a wide range of market conditions. But both Kimberly-Clark (NYSE: KMB), the consumer goods specialist, and Johnson & Johnson....
Oddly, Juno Therapeutics Is Jumping 11.3% Today
Despite a 6.1 million-share follow-on public stock offering, shares of Juno Therapeutics (NASDAQ: JUNO) are rallying 11.3% higher at 3 p.m. EDT.Juno Therapeutics shares have been rallying since....
Oddly, Juno Therapeutics Is Jumping 11.3% Today
Despite a 6.1 million-share follow-on public stock offering, shares of Juno Therapeutics (NASDAQ: JUNO) are rallying 11.3% higher at 3 p.m. EDT.Juno Therapeutics shares have been rallying since....
Oddly, Juno Therapeutics Is Jumping 11.3% Today
Despite a 6.1 million-share follow-on public stock offering, shares of Juno Therapeutics (NASDAQ: JUNO) are rallying 11.3% higher at 3 p.m. EDT.Juno Therapeutics shares have been rallying since....
Why Exelixis, Inc. Slumped Today
Exelixis (NASDAQ: EXEL) is down 12.3% at 2:18 p.m. EDT after an analyst at Leerink Partners downgraded the biotech to market perform. Management also sold some shares, which could be contributing....